MBX Biosciences (MBX) Consolidated Net Income (2023 - 2026)

MBX Biosciences has disclosed Consolidated Net Income across 4 years of filings, most recently posting -$23.5 million for Q1 2026.

• Consolidated Net Income for Q1 2026 came in at -$23.5 million, up 1.52% year-over-year; the trailing twelve-month figure through Mar 2026 was -$86.6 million (down 17.89% YoY), and the FY2025 annual result was -$87.0 million, down 40.45% from the prior year.
• Consolidated Net Income came in at -$23.5 million for Q1 2026 at MBX Biosciences, down from -$22.1 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of -$8.8 million in Q4 2023 to a low of -$23.9 million in Q1 2025.
• The 4-year median for Consolidated Net Income is -$18.1 million (2024), against an average of -$17.4 million.
• Across the five-year window, Consolidated Net Income sank 93.56% in 2025 and increased 1.52% in 2026, its largest moves.
• MBX Biosciences' Consolidated Net Income stood at -$8.8 million in 2023, then sank by 76.25% to -$15.6 million in 2024, then slumped by 41.55% to -$22.1 million in 2025, then dropped by 6.6% to -$23.5 million in 2026.
• The last three Consolidated Net Income figures came in at -$23.5 million (Q1 2026), -$22.1 million (Q4 2025), and -$21.6 million (Q3 2025), per Business Quant data.